Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2431 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Spectranetics Q4 net loss widens

The net loss for 2008 was $4 million, or $0.12 per share, inclusive of after-tax IPR&D costs of $2.4 million, or $0.08 per share, compared with net income

Amicas to acquire Emageon

Under the terms of the agreement, a subsidiary of Amicas will commence a tender offer to acquire all of the outstanding shares of Emageon common stock for $1.82

Repros Therapeutics names new president

Prior to joining Repros, Dr Lammers was chief medical officer and member of the senior management team of EMD Serono in Rockland, Massachusetts, a division of Merck KGaA.